Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ethambutol · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Ethambutol hydrochloride | DRUG | - |
| Clarithromycin | DRUG | - |
| Azithromycin | DRUG | - |
Inclusion Criteria Patients must have: * HIV seropositivity. * Disseminated MAC. * No MAC therapy between time of last positive blood culture draw and study entry (single-agent prophylaxis allowed). * Life expectancy of at least 2 months. * Consent of parent or guardian if below legal age of conse...
Ethambutol is used for the treatment of Mycobacterium Avium-intracellulare Infection, specifically in combination with other antibiotics for disseminated Mycobacterium Avium Complex (MAC) infection in AIDS patients. It is a small molecule being developed by Pfizer, Inc. for this infectious disease indication.
Ethambutol is a small molecule antibiotic used against Mycobacterium Avium-intracellulare Infection. It works by inhibiting the synthesis of arabinogalactan in the mycobacterial cell wall, which disrupts the cell wall integrity and leads to bacterial death. This mechanism makes it effective against MAC infections.
Ethambutol is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. Pfizer is conducting clinical research on Ethambutol for the treatment of Mycobacterium Avium-intracellulare Infection.
Ethambutol is in Phase 3 clinical development for the treatment of Mycobacterium Avium-intracellulare Infection. It is an investigational drug in this indication, and it has completed one Phase 3 clinical trial. It is not yet approved for this use.
Ethambutol has been studied in one completed Phase 3 clinical trial, identified as NCT00002140. This trial was a randomized, double-blind, comparative study of azithromycin versus clarithromycin in combination with ethambutol for the treatment of disseminated Mycobacterium Avium Complex (MAC) infection in AIDS patients.
Ethambutol is a distinct antibiotic used in combination therapy for Mycobacterium Avium Complex (MAC) infection. In clinical trials, it has been studied alongside azithromycin and clarithromycin, which are other antibiotics used for MAC. Ethambutol is not the same as these drugs, but it is often used in combination with them.